Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue		$ 7,323	$ 10,056	$ 17,277	$ 22,248
Operating expenses:
Research and development	[1]	40,927	36,473	80,214	89,120
Sales and marketing	[1]	3,136	3,841	6,501	7,612
General and administrative	[1]	20,192	15,521	37,544	30,655
Depreciation, amortization, and impairment		36,522	5,610	41,366	11,124
Total operating expenses		100,777	61,445	165,625	138,511
Loss from operations		(93,454)	(51,389)	(148,348)	(116,263)
Other (income) expense
Interest income		(9,801)	(10,779)	(20,202)	(20,537)
Grants and incentives		(3,310)	(4,576)	(6,585)	(7,951)
Other (income) expense		(32,156)	1,970	(30,627)	(1,624)
Total other (income)		(45,267)	(13,385)	(57,414)	(30,112)
Net loss before income tax		(48,187)	(38,004)	(90,934)	(86,151)
Income tax recovery		(11,257)	(7,476)	(13,394)	(15,513)
Net loss		(36,930)	(30,528)	(77,540)	(70,638)
Foreign currency translation adjustment		(257)	122	(353)	(508)
Comprehensive loss		$ (37,187)	$ (30,406)	$ (77,893)	$ (71,146)
Net loss per share
Basic (USD per share)		$ (0.13)	$ (0.11)	$ (0.26)	$ (0.24)
Diluted (USD per share)		$ (0.13)	$ (0.11)	$ (0.26)	$ (0.24)
Weighted-average common shares outstanding
Basic (in shares)		294,217,013	288,905,587	293,467,753	288,357,081
Diluted (in shares)		294,217,013	288,905,587	293,467,753	288,357,081
Research fees
Revenue:
Total revenue		$ 5,453	$ 9,830	$ 15,227	$ 20,400
Licensing revenue
Revenue:
Total revenue		370	226	550	598
Milestone payments
Revenue:
Total revenue		$ 1,500	$ 0	$ 1,500	$ 1,250

[1] Exclusive of depreciation, amortization, and impairment